17.95 USD
-0.12 (-0.66%)
17.95 USD
0 (0%)
Overall ADMA gets a fundamental rating of 7 out of 10. We evaluated ADMA against 530 industry peers in the Biotechnology industry. ADMA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ADMA is not overvalued while it is showing excellent growth. This is an interesting combination. With these ratings, ADMA could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
In the past year ADMA was profitable.
In the past year ADMA had a positive cash flow from operations.
ADMA had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ADMA reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 36.83%, ADMA belongs to the top of the industry, outperforming 98.87% of the companies in the same industry.
ADMA's Return On Equity of 48.57% is amongst the best of the industry. ADMA outperforms 98.68% of its industry peers.
The Return On Invested Capital of ADMA (25.76%) is better than 98.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROIC | 25.76% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ADMA (42.87%) is better than 97.92% of its industry peers.
The Operating Margin of ADMA (34.19%) is better than 97.36% of its industry peers.
With a decent Gross Margin value of 54.71%, ADMA is doing good in the industry, outperforming 76.79% of the companies in the same industry.
ADMA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ADMA has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for ADMA has been increased compared to 1 year ago.
ADMA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ADMA has an improved debt to assets ratio.
2.2 Solvency
ADMA has an Altman-Z score of 20.81. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ADMA (20.81) is better than 89.62% of its industry peers.
The Debt to FCF ratio of ADMA is 1.78, which is an excellent value as it means it would take ADMA, only 1.78 years of fcf income to pay off all of its debts.
ADMA has a better Debt to FCF ratio (1.78) than 93.77% of its industry peers.
ADMA has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.16, ADMA is doing worse than 64.34% of the companies in the same industry.
Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Altman-Z | 20.81 |
ROIC/WACC2.92
WACC8.82%
2.3 Liquidity
ADMA has a Current Ratio of 7.13. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.13, ADMA is in the better half of the industry, outperforming 70.57% of the companies in the same industry.
ADMA has a Quick Ratio of 3.65. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
ADMA has a Quick ratio (3.65) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 92.86% over the past year.
ADMA shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.62%.
Measured over the past years, ADMA shows a very strong growth in Revenue. The Revenue has been growing by 70.84% on average per year.
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
3.2 Future
ADMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.90% yearly.
Based on estimates for the next years, ADMA will show a very strong growth in Revenue. The Revenue will grow by 21.48% on average per year.
EPS Next Y19.34%
EPS Next 2Y33.99%
EPS Next 3Y33.26%
EPS Next 5Y33.9%
Revenue Next Year20.91%
Revenue Next 2Y22.3%
Revenue Next 3Y22.2%
Revenue Next 5Y21.48%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 33.24, which means the current valuation is very expensive for ADMA.
Based on the Price/Earnings ratio, ADMA is valued cheaper than 92.64% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.19. ADMA is valued slightly more expensive when compared to this.
With a Price/Forward Earnings ratio of 20.00, ADMA is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.96% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.88, ADMA is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.24 | ||
| Fwd PE | 20 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ADMA is valued cheaper than 93.40% of the companies in the same industry.
91.51% of the companies in the same industry are more expensive than ADMA, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 105.2 | ||
| EV/EBITDA | 24.64 |
4.3 Compensation for Growth
ADMA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ADMA has a very decent profitability rating, which may justify a higher PE ratio.
ADMA's earnings are expected to grow with 33.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.72
PEG (5Y)N/A
EPS Next 2Y33.99%
EPS Next 3Y33.26%
5. Dividend
5.1 Amount
ADMA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
17.95
-0.12 (-0.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners93.5%
Inst Owner Change0%
Ins Owners2.35%
Ins Owner Change-0.5%
Market Cap4.27B
Revenue(TTM)488.56M
Net Income(TTM)209.45M
Analysts84
Price Target26.18 (45.85%)
Short Float %8.24%
Short Ratio5.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.96%
Min EPS beat(2)-1.96%
Max EPS beat(2)-1.96%
EPS beat(4)0
Avg EPS beat(4)-10.9%
Min EPS beat(4)-31.17%
Max EPS beat(4)-1.96%
EPS beat(8)3
Avg EPS beat(8)-42.78%
EPS beat(12)6
Avg EPS beat(12)-7.71%
EPS beat(16)8
Avg EPS beat(16)-5.59%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)0.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)2.16%
Revenue beat(8)6
Avg Revenue beat(8)4.26%
Revenue beat(12)10
Avg Revenue beat(12)4.8%
Revenue beat(16)14
Avg Revenue beat(16)6.2%
PT rev (1m)-5.81%
PT rev (3m)-11.68%
EPS NQ rev (1m)-0.89%
EPS NQ rev (3m)4.72%
EPS NY rev (1m)-0.28%
EPS NY rev (3m)3.23%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)1.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.24 | ||
| Fwd PE | 20 | ||
| P/S | 8.74 | ||
| P/FCF | 105.2 | ||
| P/OCF | 65.75 | ||
| P/B | 9.91 | ||
| P/tB | 10 | ||
| EV/EBITDA | 24.64 |
EPS(TTM)0.54
EY3.01%
EPS(NY)0.9
Fwd EY5%
FCF(TTM)0.17
FCFY0.95%
OCF(TTM)0.27
OCFY1.52%
SpS2.05
BVpS1.81
TBVpS1.79
PEG (NY)1.72
PEG (5Y)N/A
Graham Number4.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROCE | 32.61% | ||
| ROIC | 25.76% | ||
| ROICexc | 29.27% | ||
| ROICexgc | 29.53% | ||
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% | ||
| FCFM | 8.31% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Debt/EBITDA | 0.4 | ||
| Cap/Depr | 304.79% | ||
| Cap/Sales | 4.99% | ||
| Interest Coverage | 15.23 | ||
| Cash Conversion | 37.13% | ||
| Profit Quality | 19.39% | ||
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 | ||
| Altman-Z | 20.81 |
F-Score7
WACC8.82%
ROIC/WACC2.92
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y19.34%
EPS Next 2Y33.99%
EPS Next 3Y33.26%
EPS Next 5Y33.9%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
Revenue Next Year20.91%
Revenue Next 2Y22.3%
Revenue Next 3Y22.2%
Revenue Next 5Y21.48%
EBIT growth 1Y45.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.1%
EBIT Next 3Y45.85%
EBIT Next 5Y37.89%
FCF growth 1Y272.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y501.56%
OCF growth 3YN/A
OCF growth 5YN/A
ADMA BIOLOGICS INC / ADMA FAQ
What is the fundamental rating for ADMA stock?
ChartMill assigns a fundamental rating of 7 / 10 to ADMA.
What is the valuation status of ADMA BIOLOGICS INC (ADMA) stock?
ChartMill assigns a valuation rating of 6 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Fairly Valued.
How profitable is ADMA BIOLOGICS INC (ADMA) stock?
ADMA BIOLOGICS INC (ADMA) has a profitability rating of 6 / 10.
What is the financial health of ADMA BIOLOGICS INC (ADMA) stock?
The financial health rating of ADMA BIOLOGICS INC (ADMA) is 8 / 10.